Our top pick for
Building a portfolio
22nd Century Group, Inc is a drug manufacturers-specialty & generic business based in the US. 22nd Century Group shares (XXII) are listed on the NYSE MKT and all prices are listed in US Dollars. 22nd Century Group employs 67 staff and has a trailing 12-month revenue of around USD$28.1 million.
|52-week range||USD$0.55 - USD$4.66|
|50-day moving average||USD$3.1338|
|200-day moving average||USD$2.0876|
|Wall St. target price||USD$7|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.102|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$28.1 million|
|Gross profit TTM||USD$1.4 million|
|Return on assets TTM||-19.38%|
|Return on equity TTM||-37.14%|
|Market capitalisation||USD$563.9 million|
TTM: trailing 12 months
There are currently 7.2 million 22nd Century Group shares held short by investors – that's known as 22nd Century Group's "short interest". This figure is 10% down from 8.0 million last month.
There are a few different ways that this level of interest in shorting 22nd Century Group shares can be evaluated.
22nd Century Group's "short interest ratio" (SIR) is the quantity of 22nd Century Group shares currently shorted divided by the average quantity of 22nd Century Group shares traded daily (recently around 4.4 million). 22nd Century Group's SIR currently stands at 1.66. In other words for every 100,000 22nd Century Group shares traded daily on the market, roughly 1660 shares are currently held short.
However 22nd Century Group's short interest can also be evaluated against the total number of 22nd Century Group shares, or, against the total number of tradable 22nd Century Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case 22nd Century Group's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 22nd Century Group shares in existence, roughly 50 shares are currently held short) or 0.0537% of the tradable shares (for every 100,000 tradable 22nd Century Group shares, roughly 54 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against 22nd Century Group.
Find out more about how you can short 22nd Century Group stock.
We're not expecting 22nd Century Group to pay a dividend over the next 12 months.
22nd Century Group's shares were split on a 2:1 basis on 29 November 2010. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your 22nd Century Group shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for 22nd Century Group shares which in turn could have impacted 22nd Century Group's share price.
Over the last 12 months, 22nd Century Group's shares have ranged in value from as little as $0.55 up to $4.66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while 22nd Century Group's is 1.7336. This would suggest that 22nd Century Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.
Steps to owning and managing PNRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing PINC, with 24-hour and historical pricing before you buy.
Steps to owning and managing POAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTS, with 24-hour and historical pricing before you buy.
Steps to owning and managing PTMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPOP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLYA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAGP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.